Top

Cancer Chemotherapy and Pharmacology

Published in:

01-03-2016 | Original Article

UCA1 overexpression predicts clinical outcome of patients with ovarian cancer receiving adjuvant chemotherapy

Authors: Ling Zhang, Xili Cao, Liqian Zhang, Xuelin Zhang, Haihui Sheng, Kun Tao

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2016

Abstract

Purpose

Urothelial carcinoma associated 1 (UCA1) functions as an oncogene, which promotes cancer cell proliferation, invasion, and metastasis, and is responsible for drug resistance. This study aimed to determine the expression level of UCA1 in ovarian cancer and to further investigate its clinical significance.

Methods

The expression levels of UCA1 in ovarian cancer and normal ovaries were determined by quantitative real-time PCR. The relationship between UCA1 expression and clinical features and the prognostic value of UCA1 for overall survival were examined.

Results

UCA1 expression in ovarian cancer tissues was significantly upregulated compared with normal ovarian tissues. High UCA1 expression was related to lymph node metastasis, FIGO stage, and response to chemotherapy. Kaplan–Meier analysis demonstrated that high UCA1 expression was associated with poorer overall survival in patients with ovarian cancer. Cox proportional hazards analysis showed that high UCA1 expression was an independent prognostic marker of poor outcome. This effect remained significant in the further stratification analysis.

Conclusions

Our findings provided the first evidence that UCA1 may serve as an indicator of response to chemotherapy and prognosis of ovarian cancer. UCA1 may play an important role in the progression of ovarian cancer.

Knutson KL, Karyampudi L, Lamichhane P, Preston C (2015) Targeted immune therapy of ovarian cancer. Cancer Metastasis Rev 34:53–74CrossRefPubMed

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108CrossRefPubMed

Elgar G, Vavouri T (2008) Tuning into the signals: noncoding sequence conservation in vertebrate genomes. Trends Genet 24:344–352CrossRefPubMed

Zhang X, Xu Y, He C, Guo X, Zhang J, He C, Zhang L, Kong M, Chen B, Zhu C (2015) Elevated expression of CCAT2 is associated with poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol 111:834–839CrossRefPubMed

ENCODE Project Consortium (2007) Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447:799–816CrossRef

Wang KC, Chang HY (2011) Molecular mechanisms of long noncoding RNAs. Mol Cell 43:904–914PubMedCentralCrossRefPubMed

Gan L, Xu M, Zhang Y, Zhang X, Guo W (2015) Focusing on long noncoding RNA dysregulation in gastric cancer. Tumour Biol 36:129–141CrossRefPubMed

Guo G, Kang Q, Chen Q, Chen Z, Wang J, Tan L, Chen JL (2014) High expression of long non-coding RNA H19 is required for efficient tumorigenesis induced by Bcr-Abl oncogene. FEBS Lett 588:1780–1786CrossRefPubMed

Harries LW (2012) Long non-coding RNAs and human disease. Biochem Soc Trans 40:902–906CrossRefPubMed

10.

Kitagawa M, Kotake Y, Ohhata T (2012) Long non-coding RNAs involved in cancer development and cell fate determination. Curr Drug Targets 13:1616–1621CrossRefPubMed

11.

Salameh A, Lee AK, Cardo-Vila M, Nunes DN, Efstathiou E, Staquicini FI, Dobroff AS, Marchio S, Navone NM, Hosoya H, Lauer RC, Wen S, Salmeron CC, Hoang A, Newsham I, Lima LA, Carraro DM, Oliviero S, Kolonin MG, Sidman RL, Do KA, Troncoso P, Logothetis CJ, Brentani RR, Calin GA, Cavenee WK, Dias-Neto E, Pasqualini R, Arap W (2015) PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3. Proc Natl Acad Sci USA 112:8403–8408PubMedCentralCrossRefPubMed

12.

Zheng Q, Wu F, Dai WY, Zheng DC, Zheng C, Ye H, Zhou B, Chen JJ, Chen P (2015) Aberrant expression of UCA1 in gastric cancer and its clinical significance. Clin Transl Oncol 17:640–646CrossRefPubMed

13.

Morlando M, Ballarino M, Fatica A (2015) Long non-coding RNAs: new players in hematopoiesis and leukemia. Front Med (Lausanne) 2:23

14.

Yang C, Li X, Wang Y, Zhao L, Chen W (2012) Long non-coding RNA UCA1 regulated cell cycle distribution via CREB through PI3-K dependent pathway in bladder carcinoma cells. Gene 496:8–16CrossRefPubMed

15.

Wang F, Ying HQ, He BS, Pan YQ, Deng QW, Sun HL, Chen J, Liu X, Wang SK (2015) Upregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway. Oncotarget 6:7899–7917PubMedCentralCrossRefPubMed

16.

Wang HM, Lu JH, Chen WY, Gu AQ (2015) Upregulated lncRNA-UCA1 contributes to progression of lung cancer and is closely related to clinical diagnosis as a predictive biomarker in plasma. Int J Clin Exp Med 8:11824–11830PubMedCentralPubMed

17.

Wang F, Li X, Xie X, Zhao L, Chen W (2008) UCA1, a non-protein-coding RNA up-regulated in bladder carcinoma and embryo, influencing cell growth and promoting invasion. FEBS Lett 582:1919–1927CrossRefPubMed

18.

Tsang WP, Wong TW, Cheung AH, Co CN, Kwok TT (2007) Induction of drug resistance and transformation in human cancer cells by the noncoding RNA CUDR. RNA 13:890–898PubMedCentralCrossRefPubMed

19.

Xue M, Li X, Li Z, Chen W (2014) Urothelial carcinoma associated 1 is a hypoxia-inducible factor-1alpha-targeted long noncoding RNA that enhances hypoxic bladder cancer cell proliferation, migration, and invasion. Tumour Biol 35:6901–6912CrossRefPubMed

20.

Han Y, Yang YN, Yuan HH, Zhang TT, Sui H, Wei XL, Liu L, Huang P, Zhang WJ, Bai YX (2014) UCA1, a long non-coding RNA up-regulated in colorectal cancer influences cell proliferation, apoptosis and cell cycle distribution. Pathology 46:396–401CrossRefPubMed

21.

Wang F, Zhou J, Xie X, Hu J, Chen L, Hu Q, Guo H, Yu C (2015) Involvement of SRPK1 in cisplatin resistance related to long non-coding RNA UCA1 in human ovarian cancer cells. Neoplasma 62:432–438CrossRefPubMed

22.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216CrossRefPubMed

23.

Ma MZ, Chu BF, Zhang Y, Weng MZ, Qin YY, Gong W, Quan ZW (2015) Long non-coding RNA CCAT1 promotes gallbladder cancer development via negative modulation of miRNA-218-5p. Cell Death Dis 6:e1583PubMedCentralCrossRefPubMed

24.

Fang Z, Wu L, Wang L, Yang Y, Meng Y, Yang H (2014) Increased expression of the long non-coding RNA UCA1 in tongue squamous cell carcinomas: a possible correlation with cancer metastasis. Oral Surg Oral Med Oral Pathol Oral Radiol 117:89–95CrossRefPubMed

25.

Tian Y, Zhang X, Hao Y, Fang Z, He Y (2014) Potential roles of abnormally expressed long noncoding RNA UCA1 and Malat-1 in metastasis of melanoma. Melanoma Res 24:335–341CrossRefPubMed

26.

Wang T, Yuan J, Feng N, Li Y, Lin Z, Jiang Z, Gui Y (2014) Hsa-miR-1 downregulates long non-coding RNA urothelial cancer associated 1 in bladder cancer. Tumour Biol 35:10075–10084CrossRefPubMed

27.

Liu SP, Yang JX, Cao DY, Shen K (2013) Identification of differentially expressed long non-coding RNAs in human ovarian cancer cells with different metastatic potentials. Cancer Biol Med 10:138–141PubMedCentralPubMed

28.

Xue M, Li X, Wu W, Zhang S, Wu S, Li Z, Chen W (2014) Upregulation of long non-coding RNA urothelial carcinoma associated 1 by CCAAT/enhancer binding protein alpha contributes to bladder cancer cell growth and reduced apoptosis. Oncol Rep 31:1993–2000PubMedCentralPubMed

29.

Wang X, Gong Y, Jin B, Wu C, Yang J, Wang L, Zhang Z, Mao Z (2014) Long non-coding RNA urothelial carcinoma associated 1 induces cell replication by inhibiting BRG1 in 5637 cells. Oncol Rep 32:1281–1290PubMedCentralPubMed

30.

Xu Y, Pan Q, Wang C, He C, Su Z, Guo X, Zhang J, Kong M, Ke S, Zhang J, Chen B, Sheng H, Zhang X (2014) Genetic polymorphisms in oxidative stress-related genes are associated with clinical outcome in patients with advanced non-small cell lung cancer receiving tyrosine kinase inhibitors. Am J Cancer Res 4:934–942PubMedCentralPubMed

31.

Li HJ, Li X, Pang H, Pan JJ, Xie XJ, Chen W (2015) Long non-coding RNA UCA1 promotes glutamine metabolism by targeting miR-16 in human bladder cancer. Jpn J Clin Oncol 45:1055–1063CrossRefPubMed

32.

Fan Y, Shen B, Tan M, Mu X, Qin Y, Zhang F, Liu Y (2014) Long non-coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling. FEBS J 281:1750–1758CrossRefPubMed

33.

Cheng N, Cai W, Ren S, Li X, Wang Q, Pan H, Zhao M, Li J, Zhang Y, Zhao C, Chen X, Fei K, Zhou C, Hirsch FR (2015) Long non-coding RNA UCA1 induces non-T790 M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer. Oncotarget 6:23582–23593PubMedCentralCrossRefPubMed

Title: UCA1 overexpression predicts clinical outcome of patients with ovarian cancer receiving adjuvant chemotherapy
Authors: Ling Zhang
Xili Cao
Liqian Zhang
Xuelin Zhang
Haihui Sheng
Kun Tao
Publication date: 01-03-2016
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 3/2016
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-016-2963-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2016

A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer

Protective effects of mito-TEMPO against doxorubicin cardiotoxicity in mice

Targeting hedgehog signaling pathway in pediatric tumors: in vitro evaluation of SMO and GLI inhibitors

Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer

Meta-analysis of published efficacy and safety data for docetaxel in second-line treatment of patients with advanced non-small-cell lung cancer

Phase I trial of nedaplatin chemotherapy concurrent with radiotherapy for untreated locoregionally advanced nasopharyngeal carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer